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Background: Sepsis is a serious disease condition and a major cause of intensive care unit (ICU) admission. Its
diagnosis in critically ill patients is complicated. To diagnose an infection rapidly, and to accurately differentiate
systemic inflammatory response syndrome (SIRS) from sepsis, is challenging yet early diagnosis is vital for early
induction of an appropriate therapy. The aim of this study was to evaluate whether the immature granulocyte (IG)
count is a useful early diagnostic marker of sepsis compared to other markers. Therefore, a total of 70 consecutive
surgical intensive care patients were assessed. IGs were measured from whole blood samples using an automated
analyzer. C-reactive protein (CRP), lipopolysaccharide binding protein (LBP) and interleukin-6 (IL-6) concentrations
were also determined. The observation period was a maximum of 21 days and ended with the patients’ discharge
from ICU or death. Receiver operating characteristic (ROC) analyses were conducted and area under the curve
(AUC) was calculated to determine sensitivities and specificities for the parameters.
Results: We found that the IG count significantly discriminates between infected and non-infected patients
(P < 0.0001) with a sensitivity of 89.2% and a specificity of 76.4%, particularly within the first 48 hours after SIRS
onset. Regarding the discriminative power for infection, the IG count was more indicative than other clinical
parameters such as CRP, LBP and IL-6, which had a sensitivity of less than 68%. Additionally, the highest diagnostic
odds ratio (DOR) with 26.7 was calculated for the IG count within the first 48 hours. During the course of the
disease ROC curve analyses showed a superior positive predictive value of the IG count compared to the other
measured parameters during the first five days following the fulfillment of SIRS criteria. However, the number of IGs
was not correlated with ICU mortality.
Conclusions: The total number of IG in peripheral blood from ICU patients is a good marker to discriminate
infected and non-infected patients very early during SIRS. However, the IG count is not suitable as a prognostic
marker for mortality. Routine and serial measurement of IGs may provide new possibilities for rapid screening of
SIRS patients on ICU with suspected infections.* Correspondence: nierhaus@uke.de
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In 1992, the American College of Chest Physicians (ACCP)
and the Society of Critical Care Medicine (SCCM) esta-
blished criteria to define and distinguish systemic inflam-
matory response syndrome (SIRS) and sepsis. According to
the ACCP/SCCM consensus conference both SIRS and
sepsis are characterized by the occurrence of at least two
of the following conditions: (1) body temperature >38°C or
<36°C; (2) heart rate >90 beats per minute; (3) respiratory
rate >20 breaths per minute or PaCO2 <32 mm Hg;
(4) white blood cell count >12,000/cu mm, <4000/cu mm,
or >10% immature (band) forms. In addition to these
criteria, the term sepsis is defined as an inflammatory
systemic response arising from an infection [1]. However,
this definition of sepsis does not allow accurate staging or
prognosis of the host response to infection which is why
an expanded list of sepsis markers may reflect the clinical
response to infection more appropriately [2].
Despite an increased understanding of the pathophy-
siology of sepsis and advances in intensive care (ICU)
treatment, sepsis still results in considerable morbidity
and mortality [3,4]. Early diagnosis in critically ill
patients is required to treat inflammation and to avoid
the loss of efficacy of targeted anti-infective therapies
due to late administration [5]. Good clinical markers
should detect infection with high sensitivity and specifi-
city at an early point in time. To date, there is no reliable
method of diagnosing sepsis early in the severe syn-
drome. Microbiological blood cultures are used to iden-
tify pathogens but, in addition to their low specificity,
they are a poor early marker because of the time needed
to obtain results [6,7].
Markers such as interleukin-6 (IL-6), C-reactive protein
(CRP) and lipopolysaccharide binding protein (LBP) have
been proposed for diagnosing or monitoring sepsis [7,8].
IL-6 is produced by cells of the innate immune system
enhancing, as a secreted pro-inflammatory cytokine, early
inflammation [9]. Under septic conditions IL-6 is also pro-
duced by the endothelium and participates in leukocyte
recruitment to organs [10]. Circulating IL-6 levels seem to
be correlated with the severity of sepsis [11,12]. An
increased IL-6 level also activates the production of acute
phase proteins such as CRP and LBP [13,14]. Although
CRP has been reported as an indicator of sepsis, several
studies have demonstrated increased CRP associated with
non-infectious conditions, e.g. major surgery, cardiogenic
shock and major trauma [15-17]. LBP is a key participant
in the inflammatory response to bacterial infections
forming complexes with lipopolysaccharides (LPS) of
gram-negative bacteria [18]. Thus, monocytes and
macrophages are activated, resulting in the production
of pro-inflammatory cytokines and therefore in an en-
hancement of the clinical presentation of sepsis. How-
ever, the correlation between LBP and sepsis remainscontroversial and findings are contradictory: although
elevated LPB concentrations were found to be related to
the severity of infection no significant difference could
be shown between patients with SIRS and those with
sepsis [19,20]. In summary, these biomarkers increase in
patients with inflammation due to trauma or surgery,
and therefore their diagnostic relevance in critically ill
patients with sepsis is far from perfect [21].
The presence of immature granulocytes (IG) in the
peripheral blood provides important information indica-
ting enhanced bone marrow activity. Evaluation of the
IG count is therefore a promising option in sepsis [22].
In recent studies the appearance of IG in neonatal sep-
sis, determined with an automated system, was related
to mortality [23,24]. In this context, a left shift of granu-
lopoiesis, i.e. an increased number of neutrophil granu-
locytes or an increased immature/total granulocyte ratio
(I/T-ratio), was correlated to sepsis [25].
The present study was conducted to determine the
utility of IG# to distinguish between patients with SIRS
and those with sepsis.
Results
Patients’ characteristics
Seventy consecutive patients fulfilling at least two SIRS
criteria [1] were enrolled in the study. Their mean age was
52.4 years (range 19 – 88) and their median ICU length of
stay (LOS) was 19.5 days (range 3 – 54). The 28-day, ICU
and hospital mortality rates were: 20% (14/70 patients),
27.1% (19/70 patients) and 28.6% (20/70 patients), respec-
tively. Data were analyzed separately for patients without
infection (Group 1, n = 19) or with sepsis (Group 2, n = 51).
Group 1 consisted of patients where the presence of a pri-
mary infectious focus was unlikely (blunt trauma, solid
organ malignancy, GI-bleeding), whereas the majority of
patients in group 2 had a definitive infectious source (peri-
tonitis, penetrating trauma, ileus [cf. Table 1]). Positive
blood cultures (group 2) showed a variety of pathogens,
including aerobic gram-negative pathogens, aerobic gram-
positive pathogens and fungi. There was no difference in
ICU mortality between the two groups (26.3% non-
infected patients vs. 29.2% infected patients). Also the
LOS was not significantly different between survivors and
non-survivors in either the non-infected (P = 0.052) or
infected (P = 0.901) groups. To characterize disease seve-
rity the SAPS II score was determined on the day of ICU
admission. The population had a median SAPS II score of
37 indicating an expected ICU mortality of 19.7% (the
observed overall ICU mortality was 27.1%). As expected,
the SAPS II score for non-survivors (n = 19) was signifi-
cantly higher than for survivors (n = 51) (p = 0.012) with
(data not shown). No difference of SAPS II score between
survivors and non-survivors was observed in the non-
infected or infected patient sub-groups. Patients’ pre-
Table 1 Patient characteristics
Characteristic All No infection Infection
Patient numbers 70 19 51
Age (yr) (median, range) 52.9 (19 – 88) 48.0 (21 – 82) 54.4 (19 – 88)
Male / Female 51 / 19 17 / 2 34 / 17
ICU LOS, days
Median (range) 19.5 (3 – 54) 15.1 (3 – 54) 21.1 (5 – 51)
95% CI 17.2 – 21.8 9.2 – 20.9 18.9 – 23.4
ICU mortality (no.) (%) 19 (27.1) 5 (26.3) 14 (27.5)
Pre-study diagnosis
Tumor 14 5 9
Trauma 22 10 12
Cardiac decompensation 4 1 3
Pancreatitis 5 0 5
Peritonitis/Mediastinitis 11 0 11
Ileus 5 0 5
Others 9 3 6






Antibiotic treatment 18 51
Data are given in absolute numbers or median (range) unless specified otherwise (n = 70). Pre study diagnoses with n < 3 are summarized as others. yr = year; ICU
= intensive care unit; LOS = length of stay; 95% CI = 95% confidence interval.
*: pathogens in the “no infection” group were isolated at a later stage during the ICU stay and were regarded as colonisation. #: all pathogens in the “infection”
group were isolated from blood cultures.
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Table 1.
Superior discriminative power for infection of IG#
ROC analyses were performed to compare the diagnostic
performance of four clinical parameters of their predictive
potential for sepsis: IG#, CRP, LBP and IL-6. IG# showed
a significant distinction between infected and non-
infected patients. Thus, a P = 0.015 was determined for
IG# vs. CRP, P = 0.022 for IG# vs. LBP and P = 0.003 for
IG# vs. IL-6 (data not shown). The superior discriminative
power of IG# compared to the other parameters was
underlined by its high sensitivity of 89.2% along with a
specificity of 76.4% (Figure 1). The highest AUC value of
all detected parameters within the first 48 hours after SIRS
alert was given by IG# with AUC= 0.861 (P < 0.0001). The
sensitivities of CRP, LBP and IL-6 did not reach 68% with
AUC values below 0.65 (0.529 – 0.648).
Further statistical analysis for independent samples
demonstrated the superior discriminative power of IG#
over the other parameters (Table 2). Patients with an infec-
tion had a significantly higher mean IG# than thosewithout an infection (P < 0.0001). Thus, it was possible to
distinguish patients with or without infection based on the
total number of IGs within the first 48 hours after SIRS
criteria had been fulfilled. However, an overlap of IG# was
observed between the two groups, with 427.6 +/− 1376.2
cells/μl in patients without an infection and 630.5 +/−
1042.5 cells/μl in patients with an infection. LBP, IL-6 and
SOFA were also determined and showed a significant but
smaller difference between the two groups. No significant
difference for CRP within the first 48 hours was observed
between patients with or without infection (Table 2).
In order to determine the dynamic response to sepsis,
the parameters were further analyzed over the course of
21 days after the initial SIRS alert. Five periods were
considered; period 1 (days 1–2), period 5 (days 3–5),
period 10 (days 6–9), period 15 (days 10–14), and period
20 (days 15–21). The mean value for each period was cal-
culated for each parameter. Since data did not follow a
normal distribution, the Mann Whitney U-test was used
for further analysis.
The five clinical parameters, IG#, CRP, LBP, IL-6 and
SOFA score were analyzed for their discriminative power
Figure 1 Diagnostic performance of measured parameters
within the first 48 hours. Receiver operating characteristic (ROC)
curves and area under the curves (AUC) were computed to compare
the ability of different clinical parameters to predict infection. ROC
curves are plotted and corresponding AUC values are given in the
table. P < 0.05 was considered a significant difference and is
indicated with *. IG#, immature granulocyte count; CRP, C-reactive
protein; LBP, lipopolysaccharide binding protein; IL-6, interleukin-6.
Figure 2 Prediction of infection. Predictive value of clinical
parameters for infection was computed using receiver operating
characteristic (ROC) curves and area under the curve (AUC).
Parameter differences between non-infected vs. infected patients
were assessed using Mann–Whitney U-test; significance is quoted as
P < 0.05*; P < 0.005**; P < 0.0005*** (n = 70). Positive predictive value
[PPV] and negative predictive value [NPV] were calculated for each
period; infection prevalence of 55.71% in period 1, 67.14% in period
5 and 71.43% in period 10. AUC values are plotted against study
period and numerical data of AUC [PPV / NPV] are given in the
table. IG#, immature granulocyte count; CRP, C-reactive protein; LBP,
lipopolysaccharide binding protein; IL-6, interleukin-6; SOFA,
sequential organ failure assessment score.
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significant difference between non-infected and infected
patients early in period 1 and period 5, (P < 0.0001). The
same was true for LBP, IL-6 and SOFA score in period 1,
but not for CRP. The superior predictive value of IG#
towards the other measured parameters was underlined
by its high positive and negative predictive values, par-
ticularly in periods 1 and 5.
Additionally, the highest diagnostic odds ratio (DOR)
was calculated for IG# in period 1 with 26.7 (Table 3).
For all other clinical parameters a DOR of 3.8 was not
exceeded in period 1. By period 5 and 10 the DOR for
IG# had decreased to 4.8.Table 2 Detection of infection within the first 48 hours
Non-infected Infected P-value
IG# (cells/μl) 427.6 ± 1376.2 630.5 ± 1042.5 <0.0001***
CRP (mg/l) 132.1 ± 73.6 170.5 ± 104.3 0.077
LBP (μg/ml) 61.9 ± 44.3 81.8 ± 46.9 0.048*
IL-6 (ng/l) 457.2 ± 691.7 1789.9 ± 9514.0 0.011*
SOFA (95% CI) 9.1 (8.2 – 9.9) 7.9 (7.3 – 8.5) 0.024*
Clinical parameters of patients with or without infection were determined and
the P-value between these two groups was calculated using Student’s t test
(CRP, LBP and SOFA) or Mann–Whitney U-test (IG# and IL 6); P < 0.05*; P < 0.005**;
P < 0.0005*** (n = 70). Data are given as mean± SD or mean score value (SOFA).
IG#, immature granulocyte count; CRP, C-reactive protein; LBP,
lipopolysaccharide binding protein; IL 6, interleukin-6; SOFA, sequential
organ failure assessment score.Prognostic power for mortality of IG# in late stages
We also assessed the prognostic sensitivity and specificity
of each characteristic with respect to ICU mortality. AUC
values of each individual parameter are presented in
(Figure 3). We found that the SOFA-score significantly
differentiated between survivors and non-survivors during
the whole ICU stay with AUC values of 0.670 up to 0.786
(P = 0.0004 to <0.0001). IL-6 also provided significant
discrimination on almost all days with AUC values of
0.592 to 0.688 (P < 0.05 to <0.0001), except in period 10.
Except for a significant AUC value of 0.708 (P = 0.037) for
CRP in period 15, CRP did not predict ICU mortality. A
significant difference between survivors and non-survivors
was detected for IG# in period 15 (AUC= 0.617, P = 0.042)Table 3 Diagnostic odds ratio for infection
Period 1 (d 1–2) Period 5 (d 3–5) Period 10 (d 6–9)
IG# 26.7 [89.2 / 76.4] 7.9 [81.6 / 64.1] 4.8 [27.9 / 92.6]
CRP 3.8 [42.9 /83.3] 8.3 [89.2 / 50] 10.0 [66.7 / 83.3]
LBP 3.6 [67.3 / 63.9] 2.5 [17.6 /92] 6.9 [27.7 / 94.7]
IL-6 3.0 [54.5 / 71.4] 2.0 [48.4 / 68.5] 2.6 [32.4 / 84.6]
SOFA 3.7 [71.8 /59.0] 1.8 [65.4 / 48.3] 2.7 [81.8 / 37.2]
Diagnostic odds ratio (DOR) for infection was calculated from the sensitivities
and specificities for clinical parameters. DOR [sensitivity% / specificity%] are
given in the table for each period. IG#, immature granulocyte count; CRP,
C-reactive protein; LBP, lipopolysaccharide binding protein; IL-6, interleukin-6;
SOFA, sequential organ failure assessment.
Figure 3 Prediction of ICU mortality. The predictive value of
clinical parameters for ICU mortality was computed using receiver
operating characteristic (ROC) curves and area under the curve
(AUC). Parameter differences between survivors and non survivors
were assessed using Mann–Whitney U-test; significance is quoted as
P < 0.05*; P < 0.005**; P < 0.0005*** (n = 70). AUC values are plotted
against study period and numerical values are given in the table.
IG#, immature granulocyte count; CRP, C-reactive protein; LBP,
lipopolysaccharide binding protein; IL 6, interleukin-6; SOFA,
sequential organ failure assessment score.
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was not correlated with ICU mortality.Discussion
We have demonstrated that the IG count discriminates
between SIRS patients with and without infection. We
observed a significant difference within the first five days
after the initial SIRS alert, and particularly within the
first 48 hours (P < 0.0001). Polymorphonuclear neutro-
phil granulocytes (PMN) are the first line effectors of
host defense against bacteria and other pathogens repre-
senting about 50% to 60% of all circulating white blood
cells (WBC) [26]. Induced by granulocyte-colony stimu-
lating factor (G-CSF), PMN develop from progenitor
cells and maturate in the bone marrow over several
stages into mature segmented neutrophils [27]. After a
maturation period of seven to ten days they migrate into
the peripheral blood. Healthy individuals do not have
immature granulocytes present in their peripheral blood
and consequently the incidence of IG in the periphery
indicates substantially increased bone marrow activation
as seen in sepsis. Besides the microbiological evidence
for infection there are no other generally accepted accur-
ate clinical parameters defined by the ACCP/SCCM
Consensus Conference Committee to distinguish sepsis
from SIRS so far. Therefore we investigated changes in
immature granulocyte numbers in patients with infec-
tions. In a previous study, Selig et al. found significantlyelevated numbers of myeloid progenitor cells in patients
with bacterial infections compared with healthy controls
[28]. In another study, Ansari-Lari et al. found a signifi-
cantly higher percentage of immature granulocytes in
infected than in non-infected patients and designated a
percentage of IG of more than three (IG% > 3) as a
predictor of sepsis, with a specificity of more than 90%
[23]. In that study patients were enrolled who were
admitted to the Emergency Department or already were
hospitalized and IG% was measured over five consecu-
tive days. In the present study the focus was on patients
who were admitted to the ICU and IGs were measured
over twenty-one consecutive days. In line with these
previous findings, our study confirms that the absolute
number of immature granulocytes is significantly higher
in infected patients than in non-infected controls. We
also demonstrated that the IG count had greater sensi-
tivity and specificity (89.2% and 76.4% respectively) than
other parameters (CRP, LBP and IL-6) which all had sen-
sitivities of less than 68%.
We also compared the performance of the IG count
with CRP, LBP and IL-6, which are parameters commonly
evaluated in patients with suspected infection or sepsis.
Although all parameters except CRP were significantly
increased in infected patients, the highest discriminative
power for infection in the first 48 hours was shown by the
total number of immature granulocytes (P < 0.0001). ROC
analyses showed the highest area under the curve (AUC)
for the IG count together with the highest sensitivity
(89.2%). Only the AUC for IGs showed significance com-
pared to all other clinical parameters in the first 48 hours.
In later periods the absolute numbers of IGs showed the
highest significance for positive prediction of infection
during period 5 (days 3–5). While LBP and IL-6 levels
were not meaningful, the CRP level was significantly
elevated. Synthesis of the acute phase protein CRP is acti-
vated by the pro-inflammatory cytokine IL-6 [29], which
is in accordance with our findings since we observed a sig-
nificant discriminatory power of CRP only during period 5
whereas elevated IL-6 levels occurred within the first
48 hours. By period 10 (days 6–9) none of the evaluated
parameters were meaningful and no significant difference
in the AUC of different parameters could be observed.
This may have been due to beneficial effects of early anti-
biotic treatment given to almost every patient suspected
of having an infection. We conclude that the IG count dis-
plays superior discriminative power for infection over
CRP, LBP and IL-6, particularly within the decisive first
48 hours after the onset of SIRS.
In addition, for the first 48 hours a high diagnostic
odds ratio (DOR) for infection of 26.7 could be calcu-
lated for the IG count [30]. All other parameters such as
CRP, LBP and IL-6, had a DOR lower than 10 at any
point in time.
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LBP, IL-6 and the SOFA score to predict ICU mortality.
As expected, the SOFA score, which is well-known and
widely used as a predictor of mortality in patients with
severe sepsis [31,32], showed the greatest significant
correlation to ICU mortality during the entire observa-
tion period. A significant differentiation between survi-
vors and non-survivors was obtained from IL-6 levels in
periods 1 and 5 but surprisingly also at later stages du-
ring periods 15 (days 10–14) and 20 (days 15–21), as
well. In early stages a correlation of high IL-6 levels with
mortality in critically ill patients is well-known [33,34].
However, the correlation is not usually sustained and IL-
6 is considered to have a short half-life. The significant
values observed even during periods 15 and 20 in the
present study may be explained by the increasing relative
number of infected patients during these periods be-
cause of the earlier discharge of non-infected patients
from the ICU. Thus, the balance of the two examined
groups is skewed towards the infected population. The
significant values of the IG count for periods 15 and 20
may be interpreted in the same manner. Therefore, the
IG count may not have prognostic power for mortality
as is the case for CRP and LBP. For CRP these findings
are consistent with the literature where no correlation
was observed between CRP concentrations and the se-
verity and mortality of sepsis [35]. The prognostic power
of LBP for the occurrence of sepsis is controversial. In
one study the LBP level was significantly elevated in
non-survivors vs. survivors on days 2 and 7 [36]. In con-
trast, although a higher LBP concentration was found in
infected than in non-infected patients, a correlation be-
tween LBP and sepsis mortality could not be detected in
another study [19].
Recently, many potential biomarkers to identify sepsis
and predict disease outcome have been examined. In
particular, acute phase proteins such as procalcitonin
(PCT) have been investigated. PCT is now used as a
supportive clinical parameter to clarify diagnosis, but
due to its high negative predictive value (99%) it is more
frequently used to rule out sepsis [37]. A comparison of
the IG count with PCT in terms of positive predictive
values for sepsis should be considered for future studies.
While our findings suggest that the IG count is not
suitable as a prognostic marker for mortality it is a good
and useful early marker for distinguishing infected and
non-infected patients. Our study population included a
wide range of patients with diverse causes for ICU ad-
mission and various disease stages. The distinct correl-
ation of the IG count with the presence of infection
shows that the former parameter is representative in
general and not only valid for a special patient subgroup.
The IG parameter on the XE-2100 has been previously
validated [22]. In this study, the automated IG countwas compared to routine manual microscopy using the
National Committee for Clinical Laboratory Standards
(NCCLS) document H20-A [38], resulting in very good
agreement between the two methods with a correlation
coefficient of r = 0.9 [22]. In addition, reference values
for IGs measured in the “differential channel” were ge-
nerated and a 5th percentile of zero and a 95th percentile
of 0.03x109/L with neither gender nor age dependency
was detectable [39]. Taken together, the automated IG
count was found to be superior to manual microscopy
whilst providing fast, inexpensive, accurate and reliable
quantification, particularly for very small proportions
with counts less than 5% of total WBC [40]. Our fin-
dings are in line with a recent work by Mardi et al. [41]
who also demonstrated the ability of white cell mor-
phology to predict sepsis.
In summary, we have shown that, within the first
48 hours after the first SIRS alert, an elevated number of
immature granulocytes indicates infection. Measuring the
IG count with a fully automated hematology analyzer pro-
vides new possibilities for rapid and early screening of
SIRS patients on the ICU with suspected infections.Conclusions
Our findings demonstrate that sepsis is associated with
an increased immature granulocyte count. The IG count
can differentiate between patients with an infection and
those who are not infected, particularly within the first
critical hours after an initial SIRS alert. Using ROC ana-
lysis we found the IG count a superior biomarker for
sepsis compared to C-reactive protein, lipopolysacchar-
ide binding protein and interleukin-6.Methods
Study design
Following approval by the local Ethical Committee who
had waived the need for informed consent a total of 70
consecutive patients were included. The study population
consisted of patients aged between 18 and 90 years, who
were admitted to the surgical ICUs of the University Me-
dical Center Hamburg-Eppendorf and who developed
signs of SIRS within 48 hours of admission. Exclusion
criteria were: malignancy, immunosuppressive or immu-
nostimulatory therapy, and recent organ transplantation.
The observation period was a maximum of 21 days and
ended with the patients’ discharge from ICU or death.
For statistical analysis the patients were classified as
those with or without infection according to the ACCP/
SCCM Consensus Conference criteria. Group 1 included
patients without an infection; Group 2 included those
with an infection. Infection was diagnosed either by
blood culture or microbiological tests from catheters,
sputum specimens, intraoperative smears, etc.
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lyzed especially within the first 48 hours because of their
predictive potential for sepsis.
Determination of immature granulocyte counts
White blood cell count, percentage of immature granu-
locytes (IG%), and absolute immature granulocyte count
(IG#) were determined in blood samples using an auto-
mated hematology analyzer (XE 2100, Sysmex, Kobe,
Japan). The method is described in detail elsewhere [23]. In
short, the IG count includes promyelocytes, myelocytes
and metamyelocytes and is performed in differential chan-
nels of the analyzer. A specific surfactant induces hemolysis
of erythrocytes and the formation of ultramicroscopic pores
in the leukocyte cell membrane. The increased permeability
of leukocytes allows a polymethine dye to enter the cells
with high affinity for nucleic acid. Subsequently, the cells
are analyzed by nucleic acid fluorescence and side scatter.
Determination of other parameters
CRP was measured with a routine turbidimetric assay
(Roche Diagnostics on Hitachi Modular). Determination
of LBP was performed by immunoassay (DPC Biermann
GmbH, Bad Nauheim, Germany) and IL-6 concentra-
tions were measured in serum using an immuno-
luminometric assay (CLIA) (DPC Biermann GmbH, Bad
Nauheim, Germany).
Simplified Acute Physiology Score II (SAPS II) [42]
was obtained within the first 24 hours of ICU admission
and Sequential Organ Failure Assessment (SOFA) score
[43] was calculated daily.
Statistical methods
Data were analyzed using MedCalc for Windows, version
11.3.3.0 (MedCalc Software, Mariakerke, Belgium). The
Kolmogorov-Smirnov test was used to verify the normality
of distribution of continuous variables, with P > 0.05
considered as non-significant and thereby normally dis-
tributed. Differences between groups were assessed using
Student’s t-test for normally and Mann–Whitney U-test
for non-normally distributed variables. Computation of
dichotomous target values was performed by χ2 test.
Receiver operating characteristic (ROC) analyses were
conducted and the area under the curve (AUC) was calcu-
lated from the sensitivities and specificities for clinical
parameters. In addition, diagnostic odds ratios (DOR)
were computed; defined as [sensitivity/(1-sensitivity)] /
[(1-specificity)/specificity]. The DOR can be read as the
ratio of the odds of disease with a positive test relative to
the odds of disease with a negative test. A test is characte-
rized as useless with a DOR of 1, whereas a DOR higher
than 25 represents a useful test and a DOR higher than
100 characterizes a good test [30].Competing interest
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